HVTN Conference
Seattle | Nov 7-9, 2011
Seattle | Nov 7-9, 2011
Please note: Some files are very large. You may have to first download them onto your computer by right-clicking your mouse and choosing "Save Target As." Once saved, you can then open the files.
Presentations
Mon Nov 7
HVTN for First Timers
PrEP: Implications for HIV Vaccine Efficacy Trials
NHVREI and Social Sciene in HVTN
RAMP Scholars
- Maynard, Jim and Eaton, Niles, Orientation to the HVTN Meeting
PrEP: Implications for HIV Vaccine Efficacy Trials
- Bekker, Linda-Gail, South Africa: Her Evolving Standard of HIV Prevention
- Buchbinder, Susan, How will PrEP affect HIV vaccine trials in MSM?
- Hendrix, Craig, Pharmacokinetics and Tissue Concentrations of Tenofovir and Emtricitabine: What is Needed to Prevent Transmission?
- Marrazzo, Jeanne, Systemic vs. Topical Pre-Exposure Prophylaxis (PrEP): What Will VOICE and Other Studies Tell Us?
- Sobieszczyk, Magda, PrEP: Implications for HIV Vaccine Study Design
NHVREI and Social Sciene in HVTN
- Andrasik, Michele, U.S. MSM Recruitment & Retention Strategies
- Baker, A. Cornelius, Knowledge & Awareness of HIV Vaccine Research: Findings from Qualitative Research
- Humes, Damon, Be the Generation Bridge Project
- Little, Stacey Partnerships & Community Outreach
RAMP Scholars
- Gonzalez, Daniel A., Facilitators and Barriers to MSM Participation in HIV Vaccine Trials
Tue Nov 8
RV144 Correlates Updates
Pox Virus Vector Based HIV Vaccines Beyond RV144
Post RV144 Selection of gp120
Community Sessions
- Janes, Holly, A Statistical Perspective on the RV144 Immune Correlates Analysis
- McElrath, Julie, Cellular Immune Responses in the RV144 Correlates Analysis
- Zolla-Pazner, Susan, Back to the Future: Antibodies, Variable Regions, and the RV144 Vaccine Trial Results
Pox Virus Vector Based HIV Vaccines Beyond RV144
- Pantaleo, Giuseppe, Poxvirus Vector-Based Vaccines Beyond RV-144
Post RV144 Selection of gp120
- McLellan, Jason S., V1V2 Structure in Complex with Antibody PG9
Community Sessions
- Evaluating and Reporting Community Engagement Activities at HVTN Sites
- Mvubu, Lindiwe, Braddy, Casey, Brooks, Katie and Meyer, Genevieve, Talking about VISP
- Retention Workshop
Wed Nov 9
Viral Sieve Analysis in Vaccine Efficacy Trials: What are they teaching us?
Roundtable - New Directions in Viral Sequence Analysis for Defining Correlates of Immunity in Vaccine Trials
Ops Day
- Hertz, Tomer, Phambili Sieve Analysis
Roundtable - New Directions in Viral Sequence Analysis for Defining Correlates of Immunity in Vaccine Trials
- Allen, Todd, How Can Viral Sequencing Inform Vaccine Trials
- Bar, Katharine and Shaw, George M., Multiplicity of HIV-1 Infection in VAX003 Injection Drug Users
- Edlefsen, Paul, V2-Focused Sieve Analysis of RV144
- Mullins, James, Deep Sequencing in the Step Trial
- Williamson, Carolyn, Sieve Analysis of the Phambili /HVTN 503 Trial
Ops Day
- Bassuk, Deb and Redinger, Huguette, LDMS/CRF Discrepancy Reports on Atlas
- Ducar, Constance and Smith, Donna, Lab Program Updates
- Karg, Carissa, VISP Registry
- Karg, Carissa, HVTN 910 Overview
- Kelly, Corey and Stockton, Sharon, Data Management Quality Reports on Atlas
- Lynn, Diana, Long Term Follow-up
- McClennan, RachaelUse of Specimens: Four Degrees of Separation
- SCHARP Clinical Affairs Staff, Clinical Affairs Updates
For Questions
Michael Welke
Conference and Events Manager
Phone: 206.667.1971
Fax: 206.667.6366
mwelke@fhcrc.org